Literature DB >> 3141583

Acute sporadic non-A, non-B hepatitis in Greece.

N C Tassopoulos1, M Alikiotis, F Limotirakis, P Nicolakakis, H Mela, M Paralogou-Ioannides.   

Abstract

The influence of non-A, non-B (NANB) agent(s) on the aetiology of acute sporadic viral hepatitis and its possible transition to chronic hepatitis were studied. Acute sporadic NANB hepatitis was diagnosed in 134 (13.5%) of the 993 Greek adults who were admitted consecutively to the Western Attica General Hospital from February 1986 to September 1987. The male to female ratio was 2.1:1, and the mean age of the patients was 39.7 +/- 17.5 years (range: 16-77 years). Serological markers of past hepatitis B virus infection were detected in 32.1% of the patients. Possible risk factors occurring within 6 months of the onset of hepatitis were parenteral drug abuse in 43 (32.1%), blood transfusions in 26 (19.4%), possibly iatrogenic in 22 (16.4%), homosexual practice in one (0.7%) and no recognized risk factors in 42 (31.4%) patients. The most common source of infection was parenteral drug abuse (65%) in patients less than 30 years old and unknown (41.9%) in patients older than 30 years old. Chronic hepatitis, defined by biochemical criteria, was observed in 55.6% of the cases irrespective of the risk factor. These data show that parenteral drug abuse made a significant contribution to the spread of NANB agent(s) but not homosexual practice and that the rate of chronicity was high.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3141583     DOI: 10.1002/jmv.1890260110

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  3 in total

1.  Treatment of acute non-A, non-B hepatitis with interferon alpha-2b.

Authors:  N C Tassopoulos; M Koutelou; G Papatheodoridis; H Polychronaki; T Giannikakis; M Paraloglou-Ioannides; A Hatzakis
Journal:  Infection       Date:  1992 Jul-Aug       Impact factor: 3.553

2.  Sexual transmission of hepatitis C virus and HIV-1 infection in female intravenous drug users.

Authors:  A Salvaggio; M Conti; A Albano; A Pianetti; M L Muggiasca; M Re; L Salvaggio
Journal:  Eur J Epidemiol       Date:  1993-05       Impact factor: 8.082

3.  Recombinant human interferon alfa-2b treatment for acute non-A, non-B hepatitis.

Authors:  N C Tassopoulos; M G Koutelou; G Papatheodoridis; H Polychronaki; I Delladetsima; T Giannikakis; A Todoulos; A Toliopoulos; A Hatzakis
Journal:  Gut       Date:  1993       Impact factor: 23.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.